Literature DB >> 8388838

Molecular aspects of membrane stabilization by ursodeoxycholate [see comment].

S Güldütuna1, G Zimmer, M Imhof, S Bhatti, T You, U Leuschner.   

Abstract

BACKGROUND: Ursodeoxycholate, used for therapy in biliary liver diseases, prevents bile salt damage in animal experiments. Using isolated red blood cell and both canalicular and basolateral hepatocyte membranes, the present study examined this protective effect.
METHODS: Membranes were incubated with chenodeoxycholate, with chenodeoxycholate and ursodeoxycholate simultaneously, and first with ursodeoxycholate followed by chenodeoxycholate. Changes in membrane structure were investigated by electron paramagnetic resonance spectroscopy, using different spin labels. Data were confirmed by analysis of membrane lipids and studies with 14C-labeled bile acids.
RESULTS: The increase of polarity in the apolar domain of the membrane caused by chenodeoxycholate corresponded to the amount of solubilized lipids. After preincubation with ursodeoxycholate or its conjugates, membrane damage by subsequent chenodeoxycholate incubation was prevented. This effect was caused by binding of ursodeoxycholate in the apolar domain, of its conjugates in the interface of the membrane.
CONCLUSIONS: Chenodeoxycholate solubilizes membrane lipids and permits water to permeate into plasma membranes. The steroid nucleus of ursodeoxycholate is bound to the apolar domain and that of the conjugates to the interface of the membrane, thus stabilizing membrane structure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388838     DOI: 10.1016/0016-5085(93)90653-t

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  29 in total

1.  Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment.

Authors:  M Leuschner; C F Dietrich; T You; C Seidl; J Raedle; G Herrmann; H Ackermann; U Leuschner
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

2.  In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids.

Authors:  Sui Peng; Xiaofang Huo; Davood Rezaei; Qiuyang Zhang; Xi Zhang; Chunhua Yu; Kiyotaka Asanuma; Edaire Cheng; Thai H Pham; David H Wang; Minhu Chen; Rhonda F Souza; Stuart Jon Spechler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-22       Impact factor: 4.052

3.  The ursodeoxycholic acid story in primary biliary cirrhosis.

Authors:  A G Lim; R P Jazrawi; T C Northfield
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

4.  Protective effect of tauroursodeoxycholate against acute gastric mucosal injury induced by hydrophobic bile salts.

Authors:  M Muraca; E Zanusso; V Cianci; M T Vilei; P Pazzi; M Dalla Libera; S Gamberini
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 5.  Ursodeoxycholic acid in the treatment of liver diseases.

Authors:  S Saksena; R K Tandon
Journal:  Postgrad Med J       Date:  1997-02       Impact factor: 2.401

Review 6.  Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy.

Authors:  Koji Miyanishi; Toshifumi Hoki; Shingo Tanaka; Junji Kato
Journal:  World J Hepatol       Date:  2015-03-27

7.  Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress.

Authors:  Carlos Felipe Bernardes-Silva; Adérson O M C Damião; Aytan M Sipahi; Francisco R M Laurindo; Kiyoshi Iriya; Fabio P Lopasso; Carlos A Buchpiguel; Maria Laura L Lordello; Carmem L O Agostinho; Antonio A Laudanna
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

8.  Tauroursodeoxycholic acid protects cholestasis in rat reperfused livers: its roles in hepatic calcium mobilization.

Authors:  T Ono; K Imai; H Kohno; M Uchida; Y Takemoto; D K Dhar; N Nagasue
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

9.  Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells.

Authors:  R J S Viana; A F Nunes; R E Castro; R M Ramalho; J Meyerson; S Fossati; J Ghiso; A Rostagno; C M P Rodrigues
Journal:  Cell Mol Life Sci       Date:  2009-03       Impact factor: 9.261

10.  Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.

Authors:  S Güldütuna; M Leuschner; N Wunderlich; A Nickel; S Bhatti; K Hübner; U Leuschner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.